MicroRNA-4649-3p inhibits cell proliferation by targeting protein tyrosine phosphatase SHP-1 in nasopharyngeal carcinoma cells

Pan,Xiaofen; Peng,Gang; Liu,Sha; Sun,Ziyi; Zou,Zhenwei; Wu,Gang

doi:10.3892/ijmm.2015.2245

MicroRNA-4649-3p inhibits cell proliferation by targeting protein tyrosine phosphatase SHP-1 in nasopharyngeal carcinoma cells

Authors:
- Xiaofen Pan
- Gang Peng
- Sha Liu
- Ziyi Sun
- Zhenwei Zou
- Gang Wu
View Affiliations

Affiliations: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: June 12, 2015 https://doi.org/10.3892/ijmm.2015.2245
Pages: 559-564

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the influence of microRNA-4649-3p on nasopharyngeal carcinoma (NPC) cell proliferation and how it regulated SHP‑1 expression. The online software TargetScan was used to predict the microRNAs targeting SHP‑1 and identified that miR‑4649‑3p was one of the possible miRNAs targeting SHP‑1. Subsequently, quantitative polymerase chain reaction (PCR) was used to detect the expression level of miR‑4649‑3p and SHP‑1 mRNA in different NPC cell lines. The miR‑4649‑3p mimics and inhibitors were transfected into NPC cells and cell proliferation was examined by the MTT assay. The SHP‑1 expression level was determined by PCR and western blot analysis. Lentivirus containing the SHP‑1 gene and miR‑4649‑3p mimics was co‑transfected into the NPC cells and cell proliferation was detected by the MTT assay. The expression level of miR‑4649‑3p and SHP‑1 mRNA was negatively correlated in the NPC cell lines. miR‑4649‑3p mimics suppressed NPC cell proliferation whereas miR‑4649‑3p inhibitors promoted NPC cell proliferation. The SHP‑1 expression level was suppressed when transfected with miR‑4649‑3p mimics in NPC cells. The miR‑4649‑3p inhibitors increased SHP‑1 expression. The luciferase reporter assay showed that miR‑4649‑3p directly targeted SHP‑1 by binding to the 3'‑untranslated region of SHP‑1 mRNA. Overexpression of SHP‑1 inversed the inhibited effect of miR‑4649‑3p mimics on cell proliferation. In conclusion, miR‑4649‑3p inhibits cell proliferation by targeting SHP-1 in NPC cells.

View Figures

View References

1	Wee JT, Ha TC, Loong SL and Qian CN: Is nasopharyngeal cancer really a ‘Cantonese cancer’? Chin J Cancer. 29:517–526. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ng WT, Lee MC, Hung WM, Choi CW, Lee KC, Chan OS and Lee AW: Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol. 79:420–428. 2011. View Article : Google Scholar
3	Tham IW, Hee SW, Yeo RM, Salleh PB, Lee J, Tan TW, Fong KW, Chua ET and Wee JT: Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre singapore experience. Int J Radiat Oncol. 75:1481–1486. 2009. View Article : Google Scholar
4	Stoker SD, van Diessen JN, de Boer JP, Karakullukcu B, Leemans CR and Tan IB: Current treatment options for local residual nasopharyngeal carcinoma. Curr Treat Options Oncol. 14:475–491. 2013. View Article : Google Scholar : PubMed/NCBI
5	Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T and Zaatar A: Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis. J Natl Cancer I. 105:595–605. 2013. View Article : Google Scholar
6	Dahabreh IJ, Linardou H, Siannis F, Fountzilas G and Murray S: Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials. Oncologist. 13:620–630. 2008. View Article : Google Scholar : PubMed/NCBI
7	Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
8	Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol. 23:4265–4274. 2005. View Article : Google Scholar : PubMed/NCBI
9	Cheng AL, Li J, Vaid AK, Ma BB, Teh C, Ahn JB, Bello M, Charoentum C, Chen LT, de Lima Lopes G Jr, et al: Adaptation of international guidelines for metastatic colorectal cancer: An asian consensus. Clin Colorectal Cancer. 13:145–155. 2014. View Article : Google Scholar : PubMed/NCBI
10	Adachi T, Hinoi T, Egi H, Shimomura M and Ohdan H: Oxaliplatin and molecular-targeted drug therapies improved the overall survival in colorectal cancer patients with synchronous peritoneal carcinomatosis undergoing incomplete cytoreductive surgery. Surg Today. Aug 26–2014.Epub ahead of print.
11	Chua DT, Wei WI, Wong MP, Sham JS, Nicholls J and Au GK: Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck. 30:863–867. 2008. View Article : Google Scholar : PubMed/NCBI
12	Ma B, Hui EP, King A, To KF, Mo F, Leung SF, Kam M, Lo YM, Zee B, Mok T, Ahuja A, et al: A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol. 62:59–64. 2008. View Article : Google Scholar
13	Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, et al: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 25:3766–3773. 2007. View Article : Google Scholar : PubMed/NCBI
14	Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, et al: Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 23:3568–3576. 2005. View Article : Google Scholar : PubMed/NCBI
15	Banville D, Stocco R and Shen SH: Human protein tyrosine phosphatase 1C (PTPN6) gene structure: Alternate promoter usage and exon skipping generate multiple transcripts. Genomics. 27:165–173. 1995. View Article : Google Scholar : PubMed/NCBI
16	Evren S, Wan S, Ma XZ, Fahim S, Mody N, Sakac D, Jin T and Branch DR: Characterization of SHP-1 protein tyrosine phosphatase transcripts, protein isoforms and phosphatase activity in epithelial cancer cells. Genomics. 102:491–499. 2013. View Article : Google Scholar : PubMed/NCBI
17	Peng G, Cao R, Xue J, Li P, Zou Z, Huang J and Ding Q: Increased expression of SHP-1 is associated with local recurrence after radiotherapy in patients with nasopharyngeal carcinoma. Radiol Oncol. 48:40–49. 2014. View Article : Google Scholar : PubMed/NCBI
18	Peng G, Cao RB, Li YH, Zou ZW, Huang J and Ding Q: Alterations of cell cycle control proteins SHP-1/2, p16, CDK4 and cyclin D1 in radioresistant nasopharyngeal carcinoma cells. Mol Med Rep. 10:1709–1716. 2014.PubMed/NCBI
19	Cao R, Ding Q, Li P, Xue J, Zou Z, Huang J and Peng G: SHP1-mediated cell cycle redistribution inhibits radiosensitivity of non-small cell lung cancer. Radiat Oncol. 8:1782013. View Article : Google Scholar : PubMed/NCBI
20	Li G, Qiu Y, Su Z, Ren S, Liu C, Tian Y and Liu Y: Genome-wide analyses of radioresistance-associated miRNA expression profile in nasopharyngeal carcinoma using next generation deep sequencing. PloS One. 8:e844862013. View Article : Google Scholar : PubMed/NCBI
21	Li G, Liu Y, Su Z, Ren S, Zhu G, Tian Y and Qiu Y: MicroRNA-324-3p regulates nasopharyngeal carcinoma radioresistance by directly targeting WNT2B. Eur J Cancer. 49:2596–2607. 2013. View Article : Google Scholar : PubMed/NCBI
22	Zhang H, Pu J, Qi T, Qi M, Yang C, Li S, Huang K, Zheng L and Tong Q: MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha. Oncogene. 33:387–397. 2014. View Article : Google Scholar
23	Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY: miR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007. View Article : Google Scholar
24	Cheng G: Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 81:75–93. 2014. View Article : Google Scholar : PubMed/NCBI
25	Yang Y, Gu X, Zhou M, Xiang J and Chen Z: Serum microRNAs: A new diagnostic method for colorectal cancer. Biomed Rep. 1:495–498. 2013.
26	Berger F and Reiser MF: Micro-RNAs as potential new molecular biomarkers in oncology: Have they reached relevance for the clinical imaging sciences? Theranostics. 3:943–952. 2013. View Article : Google Scholar
27	Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013. View Article : Google Scholar : PubMed/NCBI
28	Duchaine TF and Slack FJ: RNA interference and micro RNA-oriented therapy in cancer: rationales, promises, and challenges. Curr Oncol. 16:61–66. 2009. View Article : Google Scholar : PubMed/NCBI
29	Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, Neri A and Tassone P: Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets. 12:838–846. 2012. View Article : Google Scholar : PubMed/NCBI
30	Orang AV and Barzegari A: MicroRNAs in colorectal cancer: from diagnosis to targeted therapy. Asian Pac J Cancer Prev. 15:6989–6999. 2014. View Article : Google Scholar : PubMed/NCBI
31	Long Z, Wang B, Tao D, Huang Y and Tao Z: Hypofractionated radiotherapy induces miR-34a expression and enhances apoptosis in human nasopharyngeal carcinoma cells. Int J Mol Med. 34:1388–1394. 2014.PubMed/NCBI
32	Li G, Wang Y, Liu Y, Su Z, Liu C, Ren S, Deng T, Huang D, Tian Y and Qiu Y: miR-185-3p regulates nasopharyngeal carcinoma radioresistance by targeting WNT2B in vitro. Cancer Sci. 105:1560–1568. 2014. View Article : Google Scholar : PubMed/NCBI
33	Zhang C, Fang X, Li W, Shi Q, Wu L, Chen X, Huang Z, Wu P, Wang Z and Liao Z: Influence of recombinant lentiviral vector encoding miR-15a/16-1 in biological features of human nasopharyngeal carcinoma CNE-2Z cells. Cancer Biother Radiopharm. 29:422–427. 2014. View Article : Google Scholar : PubMed/NCBI
34	Li XH, Qu JQ, Yi H, Zhang PF, Yi HM, Wan XX, He QY, Ye X, Yuan L, Zhu JF, et al: Integrated analysis of differential miRNA and mRNA expression profiles in human radioresistant and radiosensitive nasopharyngeal carcinoma cells. PLoS One. 9:e877672014. View Article : Google Scholar : PubMed/NCBI
35	Zhang JX, Qian D, Wang FW, Liao DZ, Wei JH, Tong ZT, Fu J, Huang XX, Liao YJ and Deng HX: MicroRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Lett. 329:91–98. 2013. View Article : Google Scholar
36	Qu C, Liang Z, Huang J, Zhao R, Su C, Wang S, Wang X, Zhang R, Lee MH and Yang H: MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle. 11:785–796. 2012. View Article : Google Scholar : PubMed/NCBI
37	Chen ZX, Sun AM, Chen Y, Liu Y, Zhan JF, Chen LH and Yuan YW: Effects of radiosensitivity and X-ray dose on miR-7 expression in nasopharyngeal carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 30:1810–1812. 2010.In Chinese.
38	Tong L, Yuan Y and Wu S: Therapeutic microRNAs targeting the NF-kappa B signaling circuits of cancers. Adv Drug Deliv Rev. 81:1–15. 2014. View Article : Google Scholar : PubMed/NCBI
39	Zhang T, Sun Q, Liu T, Chen J, Du S, Ren C, Liao G and Yuan Y: MiR-451 increases radiosensitivity of nasopharyngeal carcinoma cells by targeting ras-related protein 14 (RAB14). Tumor Biol. 35:12593–12599. 2014. View Article : Google Scholar
40	Gandhi NS, Tekade RK and Chougule MB: Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release. 194:238–256. 2014. View Article : Google Scholar : PubMed/NCBI
41	Delibrias CC, Floettmann JE, Rowe M and Fearon DT: Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes. J Exp Med. 186:1575–1583. 1997. View Article : Google Scholar : PubMed/NCBI
42	Oka T, Yoshino T, Hayashi K, Ohara N, Nakanishi T, Yamaai Y, Hiraki A, Sogawa CA, Kondo E, Teramoto N, et al: Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am J Pathol. 159:1495–1505. 2001. View Article : Google Scholar : PubMed/NCBI
43	Sato K, Horiuchi M, Yo R and Nakarai I: A long survival case of small cell lung cancer synchronized with renal cancer. Kyobu Geka. 44:251–253. 1991.In Japanese. PubMed/NCBI
44	Amin HM, Hoshino K, Yang H, Lin Q, Lai R and Garcia-Manero G: Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (SHP-1) is associated with progression of chronic myeloid leukaemia. J Pathol. 212:402–410. 2007. View Article : Google Scholar : PubMed/NCBI
45	López-Ruiz P, Rodriguez-Ubreva J, Cariaga AE, Cortes MA and Colás B: SHP-1 in cell-cycle regulation. Anticancer Agents Med Chem. 11:89–98. 2011. View Article : Google Scholar : PubMed/NCBI